Sugarbaker Paul H
Washington Cancer Institute, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA.
Expert Opin Pharmacother. 2009 Aug;10(12):1965-77. doi: 10.1517/14656560903044974.
The peritoneal surfaces are a common site of surgical treatment failure for gastrointestinal and ovarian cancer. Progressive cancer growth at this site will result in the patient's cancer-related death. Clinical and laboratory research support new technologies to prevent disease spread to peritoneum or to treat established disease at these sites. This new treatment strategy involves a multimodality approach that combines cytoreductive surgery with perioperative intraperitoneal chemotherapy irrigations. The surgery utilizes the new surgical technique of peritonectomy, which strips away the lining of the body cavity using ball-tip electrosurgery. The surgery removes the primary cancer and any dissemination within the peritoneal cavity; the goal of the chemotherapy solution is to eradicate the microscopic residual disease. Multiple reports to date document marked survival benefits; a previously lethal condition can be cured in selected patients. Further pharmacologic research and more knowledgeable patient selection for treatment are required.
腹膜表面是胃肠道和卵巢癌手术治疗失败的常见部位。该部位癌症的进展性生长将导致患者因癌症相关原因死亡。临床和实验室研究支持采用新技术来预防疾病扩散至腹膜或治疗这些部位已确诊的疾病。这种新的治疗策略采用多模式方法，将细胞减灭术与围手术期腹腔内化疗灌洗相结合。手术采用了新的腹膜切除术手术技术，即使用球头电外科手术剥去体腔的内衬。手术切除原发性癌症以及腹膜腔内的任何播散病灶；化疗溶液的目标是根除微小残留病灶。迄今为止的多份报告证明了显著的生存获益；在部分患者中，一种先前致命的疾病可以被治愈。还需要进一步的药理学研究以及更明智地选择适合治疗的患者。
